The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

In view of the recent surge in COVID-19 cases in various parts of the country, the Delhi government has issued an advisory ...

The Delhi government has issued an advisory directing hospitals to ensure readiness for COVID-19 by securing beds, oxygen, ...

In a major and controversial policy shift, the FDA announced in a New England Journal of Medicine article that updated ...

Low uptake may reflect barriers—misinformation, access or shifting insurance coverage—not simply waning need.

FDA's new COVID-19 vaccine policy may restrict low-risk individuals' access, pending clinical trials to prove benefits.

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Vaccine opponents and skeptics in charge of federal health agencies are restricting access to COVID shots that were a signature accomplishment of President Donald Trump’s first term.

The Trump administration released a 72-page report Thursday outlining its take on what's driving "a chronic disease crisis" ...

Vaccine advisers to the FDA decided Thursday that only strains of the JN.1 variant should be targeted by updated versions of covid vaccines that will be available next fall and winter. Separately, ...

(Reuters) -A class of drugs known as Janus kinase, or JAK, inhibitors, which work by slowing down the immune system, should ...